With a strong clinical-phase pipeline, Agenus harnesses a combination of proprietary antibody platforms, which include Retrocyte Show™ and SECANT®, and revolutionary cell therapy approaches, positioning alone being a essential contributor in the biotechnology and immunotherapy arena.Retaining independence and editorial flexibility is critical to